Gilead Sciences, Inc., a noteworthy player in the biopharma market, has been trending in investment circles lately. Several wealth management firms and investment professionals have either amplified or reduced their stake in
GILD.
QRG Capital Management, Conning, Inc., Polaris Capital Management, and Philip James Wealth Management have reduced their holdings while
TD Private Client Wealth, Nexus Investment Management, New York State Teachers Retirement System, and Ascent Group have bolstered their positions. There is a mixed sentiment in the market, with
Morgan Stanley presenting a pessimistic outlook, whereas
UBS, Citi, and Mizuho reaffirming a bullish stance on GILD. The biopharmaceutical company's recent activities, such as the
OncoNano drug-delivery collaboration and the
lowering of drug costs through an agreement with the US Government, had an impact on its shares. Furthermore, the
stronger Biktarvy timeline and encouraging news relating to the
HIV pipeline update has raised its valuation. Moreover,
GILD recently outstripped Q3 earnings and revenue estimates, with numerous analysts including Citi and Cantor Fitzgerald maintaining a Buy rating. Despite some price fluctuation and sale of shares by insiders, the stock is generally expected to thrive.
Gilead Sciences GILD News Analytics from Fri, 25 Jul 2025 07:00:00 GMT to Sat, 17 Jan 2026 12:37:29 GMT -
Rating 3
- Innovation 6
- Information 7
- Rumor 4
